{
    "PFE": [
        {
            "symbol": "PFE",
            "time": 1713916800000000000,
            "displayTime": "Wednesday, April 24 2024",
            "title": "Pfizer Declares Second-Quarter 2024 Dividend",
            "text": "April 24 (Reuters) - Pfizer Inc <PFE.N>::PFIZER DECLARES SECOND-QUARTER 2024 DIVIDEND.PFIZER DECLARES SECOND-QUARTER 2024 DIVIDEND.PFIZER INC - BOARD OF DIRECTORS APPROVES QUARTERLY CASH DIVIDEND OF $0.42 PER SHARE.PFIZER INC - DECLARED A $0.42 SECOND-QUARTER 2024 DIVIDEND ON COMPANY'S COMMON STOCK."
        },
        {
            "symbol": "PFE",
            "time": 1706572800000000000,
            "displayTime": "Tuesday, January 30 2024",
            "title": "Pfizer Says Paxlovid Revenue Adjustment In Q1 Is Possible",
            "text": "Jan 30 (Reuters) - Pfizer Inc <PFE.N>::PFIZER SPOKESPERSON SAYS POSSIBLE THERE COULD BE REVENUE ADJUSTMENT IN Q1 FOR PAXLOVID AS WINDOW FOR U.S. GOVERNMENT RETURNS STILL OPEN.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;))."
        },
        {
            "symbol": "PFE",
            "time": 1706572800000000000,
            "displayTime": "Tuesday, January 30 2024",
            "title": "Pfizer Records $3.5 Bln Revenue Reversal For COVID Pill Paxlovid In Q4",
            "text": "Jan 30 (Reuters) - Pfizer Inc <PFE.N>::PFIZER CEO, IN PREPARED REMARKS, SAYS THAT CO IS FOCUSED ON EXPANDING RETAIL CONTRACTING AND OFFERINGS TO GAIN MARKET SHARE IN THE RSV VACCINE MARKET.PFIZER EXEC SAYS RECORDED $3.5 BILLION REVENUE REVERSAL FOR COVID PILL PAXLOVID IN THE FOURTH QUARTER.PFIZER SAYS Q4 RESULTS INCLUDED A $1.4 BILLION INTANGIBLE ASSET IMPAIRMENT CHARGE ASSOCIATED WITH ULCERATIVE COLITIS DRUG ETRASIMOD.PFIZER SAYS RECORDED A NEARLY $1 BILLION INTANGIBLE ASSET IMPAIRMENT FOR PNEUMOCOCCAL DISEASE PREVENTION VACCINE PREVNAR 13.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;))."
        },
        {
            "symbol": "PFE",
            "time": 1710979200000000000,
            "displayTime": "Thursday, March 21 2024",
            "title": "Haleon Announces Closing Of Secondary Global Offering By Pfizer",
            "text": "March 21 (Reuters) - HALEON PLC <HLN.L>::HALEON PLC  - CLOSING OF SECONDARY GLOBAL OFFERING BY PFIZER.HALEON PLC -  HAS REPURCHASED 102,272,727 ORDINARY SHARES (\"ORDINARY SHARES\") FROM PFIZER INC.HALEON PLC -  INTENDS TO CANCEL REPURCHASED ORDINARY SHARES.HALEON PLC - ALL PRIOR GUIDANCE, INCLUDING ON CAPITAL ALLOCATION, REMAINS UNCHANGED.HALEON PLC -  SHARE BUYBACK REPRESENTS APPROXIMATELY \u00a3315 MILLION OF \u00a3500 MILLION IN AGGREGATE THAT HALEON EXPECTS TO ALLOCATE TO SHARE BUYBACKS IN 2024.HALEON PLC: PFIZER'S INTEREST IN HALEON WILL REDUCE FROM 32% TO ABOUT 22.6%."
        }
    ]
}